Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario
Neurological Sciences · 2024
DOI: 10.1007/s10072-024-07449-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurological Sciences, 2024. Verfasst von Lorena Lorefice und 5 weiteren Autor:innen. Beteiligte Einrichtung: Multiple Sclerosis Center, Department of Medical Sciences and Public Health, University of Cagliari, via Is Guadazzonis 2, 09126, Cagliari, Italy. lo…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Immunologic Factors, Multiple Sclerosis, Relapsing-Remitting. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Multiple Sclerosis Center, Department of Medical Sciences and Public Health, University of Cagliari, via Is Guadazzonis 2, 09126, Cagliari, Italy. lorena.lorefice@hotmail.it.
- Multiple Sclerosis Center, Department of Medical Sciences and Public Health, University of Cagliari, via Is Guadazzonis 2, 09126, Cagliari, Italy.
- Department of Neurosciences, ARNAS Brotzu, Cagliari, Italy.
Zitieren
APA
Lorefice, L., Mellino, P., Frau, J., Coghe, G., Fenu, G., & Cocco, E. (2024). Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario. Neurological Sciences. https://doi.org/10.1007/s10072-024-07449-0
Vancouver
Lorefice L, Mellino P, Frau J, Coghe G, Fenu G, Cocco E. Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario. Neurological Sciences. 2024. doi:10.1007/s10072-024-07449-0
BibTeX
@article{Lorefice2024,
author = {Lorefice, Lorena and Mellino, Paolo and Frau, Jessica and Coghe, Giancarlo and Fenu, Giuseppe and Cocco, Eleonora},
title = {Ocrelizumab use in multiple sclerosis: a real-world experience in a changing therapeutic scenario},
journal = {Neurological Sciences},
year = {2024},
doi = {10.1007/s10072-024-07449-0}
}
EUVIMED